DARIOHEALTH CORP (DRIO)

US23725P2092 - Common Stock

0.9  -0.63 (-41.18%)

After market: 1.0084 +0.11 (+12.04%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DRIO. DRIO was compared to 37 industry peers in the Health Care Technology industry. DRIO has a bad profitability rating. Also its financial health evaluation is rather negative. DRIO is quite expensive at the moment. It does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year DRIO has reported negative net income.
In the past year DRIO has reported a negative cash flow from operations.
In the past 5 years DRIO always reported negative net income.
DRIO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -40.22%, DRIO is not doing good in the industry: 68.57% of the companies in the same industry are doing better.
With a Return On Equity value of -75.59%, DRIO is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -40.22%
ROE -75.59%
ROIC N/A
ROA(3y)-65.86%
ROA(5y)-75.2%
ROE(3y)-93.72%
ROE(5y)-101.81%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 39.90%, DRIO is doing worse than 74.29% of the companies in the same industry.
DRIO's Gross Margin has improved in the last couple of years.
DRIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.88%
GM growth 5Y4.19%

2

2. Health

2.1 Basic Checks

DRIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRIO has been increased compared to 1 year ago.
The number of shares outstanding for DRIO has been increased compared to 5 years ago.
DRIO has a worse debt/assets ratio than last year.

2.2 Solvency

DRIO has an Altman-Z score of -5.91. This is a bad value and indicates that DRIO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -5.91, DRIO is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.35 indicates that DRIO is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.35, DRIO perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Altman-Z -5.91
ROIC/WACCN/A
WACC12.64%

2.3 Liquidity

A Current Ratio of 1.57 indicates that DRIO should not have too much problems paying its short term obligations.
DRIO has a Current ratio (1.57) which is in line with its industry peers.
A Quick Ratio of 1.32 indicates that DRIO should not have too much problems paying its short term obligations.
The Quick ratio of DRIO (1.32) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.32

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.26% over the past year.
Looking at the last year, DRIO shows a decrease in Revenue. The Revenue has decreased by -2.11% in the last year.
Measured over the past years, DRIO shows a very strong growth in Revenue. The Revenue has been growing by 22.46% on average per year.
EPS 1Y (TTM)49.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.98%
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y38.99%
Revenue growth 5Y22.46%
Sales Q2Q%111%

3.2 Future

Based on estimates for the next years, DRIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.17% on average per year.
DRIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.97% yearly.
EPS Next Y49.5%
EPS Next 2Y22.75%
EPS Next 3Y17.17%
EPS Next 5YN/A
Revenue Next Year32.21%
Revenue Next 2Y35.73%
Revenue Next 3Y31.92%
Revenue Next 5Y51.97%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

DRIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DRIO's earnings are expected to grow with 17.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.75%
EPS Next 3Y17.17%

0

5. Dividend

5.1 Amount

DRIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

DARIOHEALTH CORP

NASDAQ:DRIO (1/8/2025, 8:00:01 PM)

After market: 1.0084 +0.11 (+12.04%)

0.9

-0.63 (-41.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners27.12%
Inst Owner Change0%
Ins Owners9.12%
Ins Owner Change1.08%
Market Cap30.69M
Analysts84.44
Price Target3.57 (296.67%)
Short Float %7.64%
Short Ratio15.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.1%
Min EPS beat(2)10.33%
Max EPS beat(2)85.87%
EPS beat(4)4
Avg EPS beat(4)39.8%
Min EPS beat(4)10.33%
Max EPS beat(4)85.87%
EPS beat(8)6
Avg EPS beat(8)22.57%
EPS beat(12)8
Avg EPS beat(12)18.29%
EPS beat(16)9
Avg EPS beat(16)10.48%
Revenue beat(2)0
Avg Revenue beat(2)-12.06%
Min Revenue beat(2)-22.51%
Max Revenue beat(2)-1.62%
Revenue beat(4)0
Avg Revenue beat(4)-10.33%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)-0.74%
Revenue beat(8)2
Avg Revenue beat(8)-9.23%
Revenue beat(12)4
Avg Revenue beat(12)-6.97%
Revenue beat(16)5
Avg Revenue beat(16)-6.23%
PT rev (1m)0%
PT rev (3m)-8.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.11%
EPS NY rev (1m)-1.01%
EPS NY rev (3m)2.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-30.79%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-1.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.68
BVpS1.72
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.22%
ROE -75.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.9%
FCFM N/A
ROA(3y)-65.86%
ROA(5y)-75.2%
ROE(3y)-93.72%
ROE(5y)-101.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.88%
GM growth 5Y4.19%
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.04%
Cap/Sales 0.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.32
Altman-Z -5.91
F-Score4
WACC12.64%
ROIC/WACCN/A
Cap/Depr(3y)10.54%
Cap/Depr(5y)30.07%
Cap/Sales(3y)2.07%
Cap/Sales(5y)1.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.98%
EPS Next Y49.5%
EPS Next 2Y22.75%
EPS Next 3Y17.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.11%
Revenue growth 3Y38.99%
Revenue growth 5Y22.46%
Sales Q2Q%111%
Revenue Next Year32.21%
Revenue Next 2Y35.73%
Revenue Next 3Y31.92%
Revenue Next 5Y51.97%
EBIT growth 1Y-16.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.8%
EBIT Next 3Y24.59%
EBIT Next 5Y20.12%
FCF growth 1Y29.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.84%
OCF growth 3YN/A
OCF growth 5YN/A